Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated September 24, 2025, titled "Glenmark Strengthens Oncology Portfolio with Hengrui s HER2 Targeting ADC For Multiple Regions".
Press Release Sep 24 2025
Filed with NSE · · 4 pages · English
Summary by 6ix AI
The agreement allows Glenmark to develop and commercialize the drug worldwide, excluding certain regions, with an upfront payment and potential milestone payments. This collaboration aligns with Glenmark's strategy to enhance access to innovative cancer therapies and addresses significant unmet medical needs.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Glenmark Pharmaceuticals Limited on 6ix
Earlier from Glenmark Pharmaceuticals
- Hengrui Pharma and Glenmark Pharmaceuticals Enter Exclusive License Agreement for HER2 ADC Trastuzumab Rezetecan (SHR-A1811)
- Press Release Sep 05 2025
- Press Release Sep 02 2025
- Glenmark Pharmaceuticals Inc., USA to launch Eribulin Mesylate Injection, 1mg/2Ml (0.5 mg/mL) Single-Dose Vials
- FY 2024-25
Later from Glenmark Pharmaceuticals
- Glenmark Pharmaceuticals Limited Press Release Oct 23 2025
- Glenmark Pharmaceuticals Inc., USA to launch Ropivacaine Hydrochloride Injection USP, 40 mg/20 mL (2mg/mL), 150 mg/30 mL (5 mg/mL), and 200 mg/20 mL (10 mg/mL) Single-Dose Vials
- Glenmark Pharmaceuticals Limited Press Release Nov 04 2025
- Glenmark Pharmaceuticals Inc., USA to launch 8.4% Sodium Bicarbonate Injection USP, 50 mEq/50 mL (1 mEq/mL) Single-Dose Vial
- Press Release Nov 10 2025
Follow Glenmark Pharmaceuticals into a list and get an email when it puts out news.
Follow Glenmark Pharmaceuticals